Eosinophilic Esophagitis - Epidemiology Forecast - 2032

DelveInsight's 'Eosinophilic Esophagitis (EoE) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of eosinophilic esophagitis (EoE) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Eosinophilic Esophagitis (EoE): Disease Understanding

Eosinophilic Esophagitis (EoE) Overview

According to the National Organization for Rare Disorders (NORD) and the American Academy of Allergy, Asthma, and Immunology (AAAAI), eosinophilic esophagitis (EoE), also known as "asthma of the esophagus," is defined as a chronic, local immune-mediated disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus, clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The major symptoms include heartburn, regurgitation, esophageal stenosis, and dysphagia, which are more frequent in young adults and children.

The diagnosis of EoE depends on the clinical manifestations and endoscopic and histological findings in esophageal mucosa biopsies. Endoscopic findings in most patients include linear grooves on the esophagus wall, concentric rings, whitish exudates that resemble candidal infection, Schatzki rings, a reduction in the size of the esophagus, and superficial tears of the mucosa after endoscope introduction. A histological diagnosis is confirmed when there are ≥15 eosinophils per high-power field (HPF).

The main aim of the treatment of EoE is not only clinical improvement but also histological improvement to prevent the development of esophageal stricture. In 2020, the American Gastroenterology Association (AGA) and the Joint Task Force on Allergy-Immunology Practice Parameters (JTF) recommended certain guidelines on the management of EoE. The therapeutic approach against EoE consists of the "3D" concept: Diet, drugs, and dilation. The patient is treated based on the severity of their symptoms or endoscopic findings, such as esophageal narrowing or stricture. Histological improvement is generally used as the primary outcome in clinical trials rather than symptomatic improvement due to the difficulty in evaluating the symptoms objectively and uniformly. It is common for these patients to modify their diet or eating behavior to avoid dysphagia or an impaction.

PPIs are useful as a first-line treatment for patients with EoE. Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission. IL-4 and IL-13 inhibitors are promising in clinical trials, and recently the Food and Drug Administration (FDA) approved DUPIXENT (dupilumab) to treat EoE in adults and pediatric patients aged 12 and older weighing at least 40 kg (which is about 88 pounds), as the first treatment for EoE. Esophageal endoscopic dilation is most commonly used in adults with established esophageal strictures. According to recent EoE consensus statements and societal guidelines, periodic dilation is considered an acceptable alternative to medical or dietary therapy in some healthy adults with EoE.

Epidemiology

The eosinophilic esophagitis (EoE) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted eosinophilic esophagitis (EoE) epidemiology segmented as the diagnosed prevalent cases of eosinophilic esophagitis (EoE), age-specific cases of eosinophilic esophagitis (EoE), and gender-specific cases of eosinophilic esophagitis (EoE). The report includes the prevalent scenario of eosinophilic esophagitis (EoE) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Eosinophilic Esophagitis (EoE) Epidemiology

The epidemiology segment also provides the eosinophilic esophagitis (EoE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent patient population of eosinophilic esophagitis (EoE) in the 7MM countries was more than 700,000 cases in 2021.

As per the estimates, the US had the highest prevalent patient population of eosinophilic esophagitis (EoE) in 2021. Among the EU5 countries, Germany had the highest diagnosed patient population of eosinophilic esophagitis (EoE), with approximately 58,000 cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed prevalent patient population of eosinophilic esophagitis (EoE), with nearly 33,000 cases in 2021.

Scope of the Report:

• Eosinophilic esophagitis (EoE) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.

• Eosinophilic esophagitis (EoE) epidemiology report and model provide an overview of the risk factors and global trends of eosinophilic esophagitis (EoE) in the seven major markets (7MM: The US, France, Germany, Italy, Spain, UK, and Japan).

• The report provides insight into the historical and forecasted patient pool of eosinophilic esophagitis (EoE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

• The report helps recognize the growth opportunities in the 7MM concerning the patient population.

• The report assesses the disease risk and burden and highlights the unmet needs of eosinophilic esophagitis (EoE).

• The report describes eosinophilic esophagitis (EoE) epidemiology by prevalent eosinophilic esophagitis (EoE) cases in the 7MM.

• The report describes the epidemiology of eosinophilic esophagitis (EoE) by diagnosed cases of eosinophilic esophagitis (EoE) in the 7MM.

• The report provides the segmentation of the eosinophilic esophagitis (EoE) epidemiology by the prevalence of eosinophilic esophagitis (EoE) based on symptoms in the 7MM.

• The report describes the eosinophilic esophagitis (EoE) epidemiology by the age-specific cases of eosinophilic esophagitis (EoE) patients in the 7MM.

• The report segments the eosinophilic esophagitis (EoE) epidemiology by gender-specific cases of eosinophilic esophagitis (EoE) in the 7MM.

Report Highlights:

• 11-year Forecast of Eosinophilic Esophagitis (EoE) Epidemiology

• 7MM Coverage

• Diagnosed Prevalent cases of Eosinophilic Esophagitis (EoE)

• Age-specific cases of Eosinophilic Esophagitis (EoE)

• Gender-specific cases of Eosinophilic Esophagitis (EoE)

KOL Views

We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern, and this will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered:

• What are the major factors that will drive the change in the patient population in indication eosinophilic esophagitis (EoE) during the forecast period (2019-2032)?

• What key findings about eosinophilic esophagitis (EoE) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?

• What would be the total number of patients with eosinophilic esophagitis (EoE) across the 7MM forecast period (2019-2032)?

• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?

• What are the disease risk, burdens, and unmet needs of eosinophilic esophagitis (EoE)?

• What are the currently available treatments for eosinophilic esophagitis (EoE)?

Reasons to buy:

The eosinophilic esophagitis (EoE) epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global eosinophilic esophagitis (EoE) market.

• Quantify patient populations in the global eosinophilic esophagitis (EoE) market to improve product design, pricing, and launch plans.

• Understand the magnitude of the eosinophilic esophagitis (EoE) population by its diagnosed prevalent cases.

• Understand the magnitude of the eosinophilic esophagitis (EoE) population by its age-specific cases.

• Understand the magnitude of the eosinophilic esophagitis (EoE) population by its gender-specific cases of eosinophilic esophagitis (EoE).

• The eosinophilic esophagitis (EoE) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.

• The eosinophilic esophagitis (EoE) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032.